Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Altimmune Inc (ALT)

Altimmune Inc (ALT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 605,119
  • Shares Outstanding, K 39,706
  • Annual Sales, $ 8,190 K
  • Annual Income, $ -49,040 K
  • 60-Month Beta 1.45
  • Price/Sales 79.56
  • Price/Cash Flow N/A
  • Price/Book 2.61
Trade ALT with:

Options Overview

Details
  • Implied Volatility 174.54%
  • Historical Volatility 55.33%
  • IV Percentile 98%
  • IV Rank 94.62%
  • IV High 179.69% on 05/05/21
  • IV Low 83.96% on 07/22/21
  • Put/Call Vol Ratio 0.51
  • Today's Volume 5,121
  • Volume Avg (30-Day) 5,992
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 65,060
  • Open Int (30-Day) 57,607

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.36
  • Number of Estimates 4
  • High Estimate -0.23
  • Low Estimate -0.42
  • Prior Year -0.54
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.52 +32.29%
on 08/19/21
17.26 -11.70%
on 09/13/21
+3.19 (+26.47%)
since 08/17/21
3-Month
8.10 +88.15%
on 07/08/21
17.26 -11.70%
on 09/13/21
-0.62 (-3.91%)
since 06/17/21
52-Week
7.80 +95.38%
on 11/09/20
24.61 -38.07%
on 02/18/21
+1.22 (+8.70%)
since 09/17/20

Most Recent Stories

More News
Altimmune to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during a fireside chat at the H.C. Wainwright 23 Annual Global...

ALT : 15.24 (-7.07%)
Are Options Traders Betting on a Big Move in Altimmune (ALT) Stock?

Investors need to pay close attention to Altimmune (ALT) stock based on the movements in the options market lately.

ALT : 15.24 (-7.07%)
Altimmune, Inc. (ALT) Reports Q2 Loss, Misses Revenue Estimates

Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 9.09% and -93.39%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

ALT : 15.24 (-7.07%)
Altimmune to Announce Second Quarter 2021 Financial Results on August 11, 2021

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2021 financial results on Wednesday, August 11, 2021.

ALT : 15.24 (-7.07%)
Will Altimmune, Inc. (ALT) Report Negative Q2 Earnings? What You Should Know

Altimmune, Inc. (ALT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ALT : 15.24 (-7.07%)
California and NYC Order Mandatory COVID-19 Testing Among Municipal Workers

/PRNewswire/ -- New COVID-19 cases continue to surge throughout , causing municipal governments to spring into action to combat the rising number of the highly infectious Delta variant cases. On Monday,...

TNXP : 0.6192 (-1.79%)
VXRT : 8.41 (+2.31%)
COCP : 1.0500 (-2.78%)
ALT : 15.24 (-7.07%)
SIXW.CN : 0.315 (-3.08%)
SIXWF : 0.2465 (-6.27%)
Biotech Stock Roundup: NTLA Surges on Study Data, EXEL & ALT Down on Updates & More

The biotech sector was in focus last week with pipeline updates from Intellia (NTLA), Exelixis (EXEL) and Regeneron (RGEN), among others.

REGN : 651.88 (-0.20%)
SNY : 48.38 (+0.39%)
BMY : 61.31 (+0.13%)
MRNA : 430.05 (-2.41%)
EXEL : 20.72 (+0.88%)
ALT : 15.24 (-7.07%)
NTLA : 157.29 (+2.24%)
Thinking about buying stock in Check Cap, ContextLogic, Marin Software, Atossa Therapeutics, or Altimmune?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CHEK, WISH, MRIN, ATOS, and ALT.

ATOS : 3.58 (+4.99%)
CHEK : 0.9900 (-1.98%)
ALT : 15.24 (-7.07%)
MRIN : 5.66 (+2.17%)
WISH : 6.54 (+3.65%)
Altimmune, Inc. (ALT) Soars 16.5%: Is Further Upside Left in the Stock?

Altimmune, Inc. (ALT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength...

ALT : 15.24 (-7.07%)
Thinking about buying stock in Catabasis Pharmaceuticals, Arrival, MannKind, Trevena, or Altimmune?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CATB, ARVL, MNKD, TRVN, and ALT.

ALT : 15.24 (-7.07%)
ARVL : 13.03 (+3.99%)
CATB : 8.54 (-6.97%)
MNKD : 4.53 (-0.66%)
TRVN : 1.3600 (+11.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Altimmune, Inc. is a clinical-stage immunotherapeutics company. It focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The company's proprietary platform technologies consist of RespirVec and Densigen. Altimmune Inc., formerly...

See More

Key Turning Points

3rd Resistance Point 17.39
2nd Resistance Point 16.93
1st Resistance Point 16.09
Last Price 15.24
1st Support Level 14.79
2nd Support Level 14.33
3rd Support Level 13.49

See More

52-Week High 24.61
Fibonacci 61.8% 18.19
Fibonacci 50% 16.20
Last Price 15.24
Fibonacci 38.2% 14.22
52-Week Low 7.80

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar